| ASSEMBLY BIOSCIENCES INC |
| USA |
| Gesundheit |
| US0453962070 / A402CB |
| V7B (Frankfurt) / ASMB (NASDAQ) |
| FRA:V7B, ETR:V7B, V7B:GR, NASDAQ:ASMB |
| - |
| https://www.assemblybio.c.. |
|
Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its current pipeline includes investigational treatments for recurrent genital herpes, hepatit..
>Volltext.. |
| 618.2 Mio. EUR |
| 339.62 Mio. EUR |
| 64.6 Mio. EUR |
| -7.5 Mio. EUR |
| -0.04 Mio. EUR |
| -0.06 EUR |
| 2.03 Mio. EUR |
| 27.86 Mio. EUR |
| -33.21 Mio. EUR |
| 13.66 |
| 132.2% |
| 99.89% |
| - |
| - |
| - |
| - |
| ASSEMBLY BIOSCIENCES, ASSEMBLY BIO, ASSEMBLY BIOSCIENCE |
| 04.09.26 |
|
||||
|
||||
|
||||
|